Clinical study on biapenem

Abstract

We have studied the clinical efficacy and safety of biapenem (BIPM), a newly developed carbapenem antibiotic.
BIPM was administered to 11 patients with respiratory infections and one patient with urinary tract infections by intravenous drip infusion. The clinical efficacy was evaluated to be excellent in 2, good in 9, fair in 1, showing 91.7% of efficacy rate.
Isolated organisms were Pseudomonas aeruginosa (4), Klebsiella pneumoniae (2), Haemophilus parainfluenzae (1), Enterococcus faecalis (1), Alcaligenes xylosoxydans (1), Serratia marcescens (1).
Of the ten strains, K. pneumoniae, S. marcescens and two cases of P. aeruginosa were eradicated, and the other cases of P. aeruginosa, E. faecalis and A. xylosoxydans persisted. H. parainfluenzae was replaced.
Side effects were not observed. In one patient, elevation of an amylase value in laboratory findings was observed.